Phaseline

Companies › Chendu DIAO Pharmaceutical Group

Chendu DIAO Pharmaceutical Group: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Metabolic and endocrine; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DA-302168S
GLP-1R agonist
GLP1RPhase 3Overweight and ObesityJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07629544DA-302168SPhase 3Overweight and ObesityMetabolic and endocrineJul 2027

Targets

GLP1R (1)

Companies with the same targets

Eli Lilly Novo Nordisk Roche Hangzhou Sciwind Biosciences Hangzhou Zhongmei Huadong Pharmaceutical Hanmi Pharmaceutical Company AstraZeneca Amgen Regeneron Pharmaceuticals Green Valley (Shanghai) Pharmaceuticals

Companies built like this

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Beijing QL Biopharmaceutical Beijing Dongfang Biotech Kailera Fresenius Kabi

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.